{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:05:17Z","timestamp":1791255917489,"version":"4.1.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Haematology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.beha.2023.101521","type":"journal-article","created":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T03:13:08Z","timestamp":1697771588000},"page":"101521","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors"],"prefix":"10.1016","volume":"36","author":[{"given":"Sudhamsh Reddy","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samarpana","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aditi","family":"Shastri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.beha.2023.101521_bib1","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2159-8290.CD-19-1011","article-title":"Advances in the treatment of acute myeloid leukemia: new drugs and new challenges","volume":"10","author":"Short","year":"2020","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.beha.2023.101521_bib2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.beha.2023.101521_bib3","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.3324\/haematol.2018.188094","article-title":"Efficacy of the combination of venetoclax and hypomethylating agents in relapsed\/refractory acute myeloid leukemia","volume":"103","author":"Aldoss","year":"2018","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.beha.2023.101521_bib4","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1182\/bloodadvances.2018016121","article-title":"Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort","volume":"2","author":"Stahl","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2021.07.031","article-title":"Myelodysplastic syndromes: a new decade","volume":"22","author":"Volpe","year":"2022","journal-title":"Clin Lymphoma, Myeloma & Leukemia"},{"issue":"15_suppl","key":"10.1016\/j.beha.2023.101521_bib6","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS7054","article-title":"Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes","volume":"39","author":"Zeidan","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.beha.2023.101521_bib7","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/blood-2016-10-696062","article-title":"Stem and progenitor cell alterations in myelodysplastic syndromes","volume":"129","author":"Shastri","year":"2017","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.beha.2023.101521_bib8","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib9","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s10555-007-9044-4","article-title":"The role of nucleoside transporters in cancer chemotherapy with nucleoside drugs","volume":"26","author":"Zhang","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"3","key":"10.1016\/j.beha.2023.101521_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1124\/mol.113.086801","article-title":"The role of human equilibrative nucleoside transporter 1 on the cellular transport of the DNA methyltransferase inhibitors 5-azacytidine and CP-4200 in human leukemia cells","volume":"84","author":"Hummel-Eisenbeiss","year":"2013","journal-title":"Mol Pharmacol"},{"issue":"3","key":"10.1016\/j.beha.2023.101521_bib11","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2008-02-140038","article-title":"Mechanisms of resistance to 5-aza-2'-deoxycytidine in human cancer cell lines","volume":"113","author":"Qin","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101521_bib12","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S0145-2126(01)00184-9","article-title":"Potential mechanisms of resistance to cytarabine in AML patients","volume":"26","author":"Galmarini","year":"2002","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.beha.2023.101521_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.febslet.2008.12.041","article-title":"Identification of a novel point mutation in ENT1 that confers resistance to Ara-C in human T cell leukemia CCRF-CEM cells","volume":"583","author":"Zimmerman","year":"2009","journal-title":"FEBS Lett"},{"issue":"3","key":"10.1016\/j.beha.2023.101521_bib14","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.bcp.2005.05.014","article-title":"Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells","volume":"70","author":"Sarkar","year":"2005","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"10.1016\/j.beha.2023.101521_bib15","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.leukres.2014.08.016","article-title":"The hENT1 and DCK genes underlie the decitabine response in patients with myelodysplastic syndrome","volume":"39","author":"Wu","year":"2015","journal-title":"Leuk Res"},{"issue":"22","key":"10.1016\/j.beha.2023.101521_bib16","doi-asserted-by":"crossref","first-page":"11941","DOI":"10.1073\/pnas.94.22.11941","article-title":"Human deoxycytidine kinase is located in the cell nucleus","volume":"94","author":"Johansson","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"10.1016\/j.beha.2023.101521_bib17","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/0006-2952(65)90175-9","article-title":"Studies of the enzymatic deamination of cytosine arabinoside. I. Enzyme distribution and species specificity","volume":"14","author":"Camiener","year":"1965","journal-title":"Biochem Pharmacol"},{"issue":"7563","key":"10.1016\/j.beha.2023.101521_bib18","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nature14948","article-title":"CDA directs metabolism of epigenetic nucleosides revealing a therapeutic window in cancer","volume":"524","author":"Zauri","year":"2015","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.beha.2023.101521_bib19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/sj.cgt.7700358","article-title":"Selection of drug-resistant transduced cells with cytosine nucleoside analogs using the human cytidine deaminase gene","volume":"8","author":"Beaus\u00e9jour","year":"2001","journal-title":"Cancer Gene Ther"},{"issue":"5","key":"10.1016\/j.beha.2023.101521_bib20","first-page":"780","article-title":"Structural analysis of the deoxycytidine kinase gene in patients with acute myeloid leukemia and resistance to cytosine arabinoside","volume":"8","author":"Flasshove","year":"1994","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.beha.2023.101521_bib21","first-page":"371","article-title":"Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity","volume":"1","author":"Kroep","year":"2002","journal-title":"Mol Cancer Therapeut"},{"issue":"5","key":"10.1016\/j.beha.2023.101521_bib22","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/S0026-895X(24)12578-3","article-title":"Phosphorylation of uridine and cytidine nucleoside analogs by two human uridine-cytidine kinases","volume":"59","author":"Van Rompay","year":"2001","journal-title":"Mol Pharmacol"},{"issue":"2","key":"10.1016\/j.beha.2023.101521_bib23","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0026-895X(25)13090-3","article-title":"Uridine-cytidine kinase. IV. Kinetics of the competition between 5-azacytidine and the two natural substrates","volume":"15","author":"Liacouras","year":"1979","journal-title":"Mol Pharmacol"},{"issue":"10","key":"10.1016\/j.beha.2023.101521_bib24","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1124\/dmd.104.000737","article-title":"A crucial role of uridine\/cytidine kinase 2 in antitumor activity of 3'-ethynyl nucleosides","volume":"32","author":"Murata","year":"2004","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.beha.2023.101521_bib25","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.exphem.2013.12.004","article-title":"Mechanisms of resistance to azacitidine in human leukemia cell lines","volume":"42","author":"Sripayap","year":"2014","journal-title":"Exp Hematol"},{"issue":"46","key":"10.1016\/j.beha.2023.101521_bib26","doi-asserted-by":"crossref","first-page":"48350","DOI":"10.1074\/jbc.M403427200","article-title":"The Dnmt1 DNA-(cytosine-C5)-methyltransferase methylates DNA processively with high preference for hemimethylated target sites","volume":"279","author":"Hermann","year":"2004","journal-title":"J Biol Chem"},{"issue":"10","key":"10.1016\/j.beha.2023.101521_bib27","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/nrm.2016.76","article-title":"Epigenetic control of adult stem cell function","volume":"17","author":"Avgustinova","year":"2016","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.beha.2023.101521_bib28","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/BF02135399","article-title":"5-Azacytidine, a new, highly effective cancerostatic","volume":"20","author":"Sorm","year":"1964","journal-title":"Experientia"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0092-8674(80)90237-8","article-title":"Cellular differentiation, cytidine analogs and DNA methylation","volume":"20","author":"Jones","year":"1980","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.beha.2023.101521_bib30","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1038\/s41375-020-1003-x","article-title":"Decitabine- and 5-azacytidine resistance emerges from adaptive responses of the pyrimidine metabolism network","volume":"35","author":"Gu","year":"2021","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.beha.2023.101521_bib31","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.3324\/haematol.2020.254482","article-title":"Mysteries of partial dihydroorotate dehydrogenase inhibition and leukemia terminal differentiation","volume":"105","author":"Saunthararajah","year":"2020","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2016.08.057","article-title":"Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia","volume":"167","author":"Sykes","year":"2016","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.beha.2023.101521_bib33","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1182\/bloodadvances.2020001461","article-title":"DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes","volume":"5","author":"Kayamori","year":"2021","journal-title":"Blood Adv"},{"issue":"49","key":"10.1016\/j.beha.2023.101521_bib34","doi-asserted-by":"crossref","first-page":"32479","DOI":"10.1074\/jbc.273.49.32479","article-title":"Diva, a Bcl-2 homologue that binds directly to Apaf-1 and induces BH3-independent cell death","volume":"273","author":"Inohara","year":"1998","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib35","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/emboj\/18.1.167","article-title":"Boo, a novel negative regulator of cell death, interacts with Apaf-1","volume":"18","author":"Song","year":"1999","journal-title":"EMBO J"},{"issue":"4","key":"10.1016\/j.beha.2023.101521_bib36","doi-asserted-by":"crossref","first-page":"490","DOI":"10.18632\/oncotarget.481","article-title":"BCL2L10 is a predictive factor for resistance to azacitidine in MDS and AML patients","volume":"3","author":"Cluzeau","year":"2012","journal-title":"Oncotarget"},{"issue":"29","key":"10.1016\/j.beha.2023.101521_bib37","doi-asserted-by":"crossref","first-page":"47103","DOI":"10.18632\/oncotarget.17482","article-title":"BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia","volume":"8","author":"Vidal","year":"2017","journal-title":"Oncotarget"},{"issue":"7377","key":"10.1016\/j.beha.2023.101521_bib38","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nature10623","article-title":"HIV-1 restriction factor SAMHD1 is a deoxynucleoside triphosphate triphosphohydrolase","volume":"480","author":"Goldstone","year":"2011","journal-title":"Nature"},{"issue":"51","key":"10.1016\/j.beha.2023.101521_bib39","doi-asserted-by":"crossref","first-page":"43596","DOI":"10.1074\/jbc.C111.317628","article-title":"Aicardi-Goutieres syndrome gene and HIV-1 restriction factor SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase","volume":"286","author":"Powell","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"10.1016\/j.beha.2023.101521_bib40","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/nm.4255","article-title":"SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia","volume":"23","author":"Schneider","year":"2017","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib41","doi-asserted-by":"crossref","first-page":"3475","DOI":"10.1038\/s41467-019-11413-4","article-title":"Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML","volume":"10","author":"Oellerich","year":"2019","journal-title":"Nat Commun"},{"issue":"7","key":"10.1016\/j.beha.2023.101521_bib42","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1038\/leu.2011.44","article-title":"Recurrent DNMT3A mutations in patients with myelodysplastic syndromes","volume":"25","author":"Walter","year":"2011","journal-title":"Leukemia"},{"issue":"17","key":"10.1016\/j.beha.2023.101521_bib43","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.beha.2023.101521_bib44","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia"},{"issue":"11","key":"10.1016\/j.beha.2023.101521_bib45","doi-asserted-by":"crossref","first-page":"e457","DOI":"10.3324\/haematol.2016.148999","article-title":"Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia","volume":"101","author":"Coombs","year":"2016","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib46","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/leu.2013.269","article-title":"Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms","volume":"28","author":"Traina","year":"2014","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib47","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1038\/s41467-018-03513-4","article-title":"RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia","volume":"9","author":"Cheng","year":"2018","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.beha.2023.101521_bib48","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1158\/1535-7163.MCT-14-0928","article-title":"MCL-1 is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor","volume":"14","author":"Xiao","year":"2015","journal-title":"Mol Cancer Therapeut"},{"issue":"20","key":"10.1016\/j.beha.2023.101521_bib49","doi-asserted-by":"crossref","first-page":"5914","DOI":"10.1158\/0008-5472.CAN-16-1248","article-title":"Finally, an apoptosis-targeting therapeutic for cancer","volume":"76","author":"Croce","year":"2016","journal-title":"Cancer Res"},{"issue":"3","key":"10.1016\/j.beha.2023.101521_bib50","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1158\/0008-5472.CAN-06-2203","article-title":"Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737","volume":"67","author":"Tahir","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.beha.2023.101521_bib51","article-title":"Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia","volume":"6","author":"Lin","year":"2016","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib52","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"issue":"12","key":"10.1016\/j.beha.2023.101521_bib53","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","author":"Ramsey","year":"2018","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/leu.2015.179","article-title":"Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients","volume":"30","author":"Jilg","year":"2016","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.beha.2023.101521_bib55","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.1182\/blood-2009-07-233304","article-title":"Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1","volume":"115","author":"Yecies","year":"2010","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.beha.2023.101521_bib56","doi-asserted-by":"crossref","first-page":"2947","DOI":"10.1182\/blood.2020008528","article-title":"Targeting Bfl-1 via acute CDK9 inhibition overcomes intrinsic BH3-mimetic resistance in lymphomas","volume":"137","author":"Boiko","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.561","article-title":"Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)","volume":"6","author":"Leverson","year":"2015","journal-title":"Cell Death Dis"},{"issue":"43","key":"10.1016\/j.beha.2023.101521_bib58","doi-asserted-by":"crossref","first-page":"70000","DOI":"10.18632\/oncotarget.12132","article-title":"Acquired resistance to venetoclax (ABT-199) in t(14;18) positive lymphoma cells","volume":"7","author":"Bodo","year":"2016","journal-title":"Oncotarget"},{"issue":"11","key":"10.1016\/j.beha.2023.101521_bib59","doi-asserted-by":"crossref","first-page":"e368","DOI":"10.1038\/bcj.2015.88","article-title":"Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)","volume":"5","author":"Phillips","year":"2015","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.beha.2023.101521_bib60","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov"},{"issue":"9","key":"10.1016\/j.beha.2023.101521_bib61","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1089\/ars.2009.3063","article-title":"The intermembrane space of mitochondria","volume":"13","author":"Herrmann","year":"2010","journal-title":"Antioxidants Redox Signal"},{"issue":"24","key":"10.1016\/j.beha.2023.101521_bib62","doi-asserted-by":"crossref","DOI":"10.1002\/pmic.201900139","article-title":"Global interactome mapping of mitochondrial intermembrane space proteases identifies a novel function for HTRA2","volume":"19","author":"Botham","year":"2019","journal-title":"Proteomics"},{"issue":"7","key":"10.1016\/j.beha.2023.101521_bib63","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","article-title":"Targeting mitochondrial structure sensitizes acute myeloid leukemia to venetoclax treatment","volume":"9","author":"Chen","year":"2019","journal-title":"Cancer Discov"},{"issue":"13","key":"10.1016\/j.beha.2023.101521_bib64","doi-asserted-by":"crossref","first-page":"7440","DOI":"10.1074\/jbc.271.13.7440","article-title":"Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2","volume":"271","author":"Zha","year":"1996","journal-title":"J Biol Chem"},{"issue":"22","key":"10.1016\/j.beha.2023.101521_bib65","doi-asserted-by":"crossref","first-page":"5589","DOI":"10.1002\/j.1460-2075.1995.tb00246.x","article-title":"A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions","volume":"14","author":"Chittenden","year":"1995","journal-title":"EMBO J"},{"issue":"5302","key":"10.1016\/j.beha.2023.101521_bib66","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1126\/science.275.5302.983","article-title":"Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis","volume":"275","author":"Sattler","year":"1997","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.beha.2023.101521_bib67","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","author":"Souers","year":"2013","journal-title":"Nat Med"},{"issue":"26","key":"10.1016\/j.beha.2023.101521_bib68","doi-asserted-by":"crossref","first-page":"4111","DOI":"10.1182\/blood-2014-03-560284","article-title":"Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma","volume":"123","author":"Fresquet","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.beha.2023.101521_bib69","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1111\/bjh.16069","article-title":"Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma","volume":"186","author":"Blombery","year":"2019","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.beha.2023.101521_bib70","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.3324\/haematol.2019.222588","article-title":"Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia","volume":"104","author":"Tausch","year":"2019","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.beha.2023.101521_bib71","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of amino acid metabolism selectively targets human leukemia stem cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.beha.2023.101521_bib72","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","author":"Lagadinou","year":"2013","journal-title":"Cell Stem Cell"},{"issue":"1","key":"10.1016\/j.beha.2023.101521_bib73","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s13045-021-01076-4","article-title":"Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine","volume":"14","author":"Buettner","year":"2021","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.beha.2023.101521_bib74","first-page":"1176","article-title":"Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells","volume":"1","author":"Stevens","year":"2020","journal-title":"Nat Can (Ott)"},{"issue":"5","key":"10.1016\/j.beha.2023.101521_bib75","doi-asserted-by":"crossref","DOI":"10.1016\/j.stem.2020.07.021","article-title":"Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells","volume":"27","author":"Jones","year":"2020","journal-title":"Cell Stem Cell"}],"container-title":["Best Practice &amp; Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000828?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692623000828?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:08:01Z","timestamp":1761498481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692623000828"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S1521692623000828"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2023.101521","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanisms of resistance to hypomethylating agents and BCL-2 inhibitors","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2023.101521","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101521"}}